Search

Suppressor of cancer cell invasion (SCAI) acts as a transcriptional repressor of serum response factor (SRF)‐mediated gene expression by binding to megakaryoblastic leukemia (MKL)/myocardin‐related transcription factor (MRTF), which is an SRF transcriptional coactivator. Growing evidence suggests that SCAI is a negative regulator of neuronal morphology, whereas MKL2/MRTFB is a positive regulator. The mRNA expression of SCAI is downregulated during brain development, suggesting that a reduction in SCAI contributes to the reduced suppression of SRF‐mediated gene induction, thus increasing dendritic complexity and developing neuronal circuits. In the present study, we hypothesized that brain‐derived neurotrophic factor (BDNF), which is important for neuronal plasticity and development, might alter SCAI mRNA levels. We therefore investigated the effects of BDNF on SCAI mRNA levels in primary cultured cortical neurons. Furthermore, because alternative splicing generates several SCAI variants in the brain, we measured SCAI variant mRNA after BDNF stimulation. Both SCAI variant 1 and total SCAI mRNA expression levels were downregulated by BDNF. Moreover, the extracellular signal‐regulated protein kinase/mitogen‐activated protein kinase (ERK/MAPK) pathway was involved in the BDNF‐mediated decrease in SCAI mRNA expression. Our findings provide insights into the molecular mechanism underlying a neurotrophic factor switch for the repressive transcriptional complex that includes SCAI. [ABSTRACT FROM AUTHOR]

The most common treatment option for patients with bullous pemphigoid is systemic corticosteroids. CYP3A4, a drug‐metabolizing enzyme in the liver, metabolizes synthetic steroids to a varying degree. Although there are many CYP3A4‐inducing drugs, several antiepileptic drugs, such as phenytoin and phenobarbital, strongly induce CYP3A4, thereby reducing the effects of corticosteroids. Here, we report a case of refractory bullous pemphigoid that rapidly improved after the discontinuation of phenytoin and phenobarbital. To achieve adequate pharmacological effects of corticosteroids, we must always ensure that patients who require corticosteroids for treatment are not medicated with CYP3A4‐inducing agents. [ABSTRACT FROM AUTHOR]

In dermatology, biologics that block signaling pathways of TNF‐α, IL‐4/IL13, IL‐17s, and IL‐23 are widely used for the treatment of several inflammatory skin diseases, such as atopic dermatitis and psoriasis. They have shown excellent efficacy with an acceptable safety profile. However, these biologics targeting pathogenic cytokines and their receptors could modulate immunological balance, leading to the development of other inflammatory or autoimmune skin diseases in some cases. In this study, we present a patient who suffered pemphigus vegetans and showed an exacerbation of pemphigus foliaceus after secukinumab loading for the treatment of complicated generalized pustular psoriasis and pyoderma gangrenosum. [ABSTRACT FROM AUTHOR]

Megakaryoblastic leukemia 2 (MKL2)/myocardin‐related transcription factor‐B (MRTFB), a serum response factor (SRF) coactivator, is an important regulator of gene expression and neuronal morphology. Here, we show that different mouse MRTFB splice isoforms, including a novel fourth MRTFB isoform named spliced neuronal long isoform of SRF transcriptional coactivator (SOLOIST)/MRTFB isoform 4 (MRTFB i4), play distinct roles in this process. SOLOIST/MRTFB i4 has a short exon that encodes 21 amino acid residues ahead of the first RPXXXEL (RPEL) motif in MRTFB isoform 3. Quantitative PCR revealed that SOLOIST/MRTFB i4 and isoform 1 were enriched in the forebrain and neurons, and up‐regulated during brain development. Conversely, isoform 3 was detected in various tissues, including both neurons and astrocytes, and was down‐regulated in the developing brain. Reporter assays supported the SRF‐coactivator function of SOLOIST/MRTFB i4 as well as isoform 1. Acute expression of MRTFB isoform 1, but not isoform 3 or SOLOIST/MRTFB i4, in neuronal cells within 24 hr drastically increased endogenous immediate early gene [c‐fos, egr1, and activity‐regulated cytoskeleton‐associated protein] expression, but not endogenous actinin α1, β‐actin, gelsolin, or srf gene expression measured by qPCR. Over‐expression of SOLOIST/MRTFB i4 reduced the dendritic complexity of cortical neurons, whereas over‐expression of isoform 1 increased this complexity. Co‐expression of isoform 1 and SOLOIST/MRTFB i4 in cortical neurons revealed that isoform 1 competitively counteracted down‐regulation by SOLOIST/MRTFB i4. Our findings indicate that MRTFB isoforms have unique expression patterns and differential effects on gene expression and dendritic complexity, which contribute to shaping neuronal circuits, at least in part. [ABSTRACT FROM AUTHOR]

The expression of immediate early genes (IEGs) is thought to be an essential molecular basis of neuronal plasticity for higher brain function. Many IEGs contain serum response element in their transcriptional regulatory regions and their expression is controlled by serum response factor (SRF). SRF is known to play a role in concert with transcriptional cofactors. However, little is known about how SRF cofactors regulate IEG expression during the process of neuronal plasticity. We hypothesized that one of the SRF‐regulated neuronal IEGs, activity‐regulated cytoskeleton‐associated protein (Arc; also termed Arg3.1), is regulated by an SRF coactivator, megakaryoblastic leukemia (MKL). To test this hypothesis, we initially investigated which binding site of the transcription factor or SRF cofactor contributes to brain‐derived neurotrophic factor (BDNF)‐induced Arc gene transcription in cultured cortical neurons using transfection and reporter assays. We found that BDNF caused robust induction of Arc gene transcription through a cAMP response element, binding site of myocyte enhancer factor 2, and binding site of SRF in an Arc enhancer, the synaptic activity‐responsive element (SARE). Regardless of the requirement for the SRF‐binding site, the binding site of a ternary complex factor, another SRF cofactor, did not affect BDNF‐mediated Arc gene transcription. In contrast, chromatin immunoprecipitation revealed occupation of MKL at the SARE. Furthermore, knockdown of MKL2, but not MKL1, significantly decreased BDNF‐mediated activation of the SARE. Taken together, these findings suggest a novel mechanism by which MKL2 controls the Arc SARE in response to BDNF stimulation. The activity‐regulated cytoskeleton‐associated protein (Arc) gene is a serum response factor (SRF) target, but little is known about its transcriptional regulation by SRF cofactors. Here, we demonstrate that SRF cofactor megakaryoblastic leukemia 2 (MKL2) binds to the Arc gene enhancer, a synaptic activity‐responsive element (SARE), and mediates brain‐derived neurotrophic factor (BDNF)‐induced Arc SARE activation. [ABSTRACT FROM AUTHOR]